ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 259 filers reported holding ACCELERON PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $12,218,000 | -4.0% | 70,996 | -30.0% | 0.91% | +7.9% |
| Q2 2021 | $12,724,000 | -7.5% | 101,396 | 0.0% | 0.84% | -12.6% |
| Q1 2021 | $13,750,000 | +6.0% | 101,396 | 0.0% | 0.96% | +33.8% |
| Q4 2020 | $12,973,000 | +13.7% | 101,396 | 0.0% | 0.72% | -48.5% |
| Q3 2020 | $11,410,000 | +18.1% | 101,396 | 0.0% | 1.39% | -15.2% |
| Q2 2020 | $9,660,000 | -10.6% | 101,396 | -15.7% | 1.64% | -34.9% |
| Q1 2020 | $10,808,000 | +6.8% | 120,264 | -37.0% | 2.52% | +28.1% |
| Q4 2019 | $10,122,000 | +34.1% | 190,977 | 0.0% | 1.97% | +27.0% |
| Q3 2019 | $7,546,000 | -3.8% | 190,977 | 0.0% | 1.55% | -6.5% |
| Q2 2019 | $7,845,000 | -11.8% | 190,977 | 0.0% | 1.66% | -25.9% |
| Q1 2019 | $8,894,000 | +6.9% | 190,977 | 0.0% | 2.24% | -17.5% |
| Q4 2018 | $8,317,000 | -23.9% | 190,977 | 0.0% | 2.71% | -3.9% |
| Q3 2018 | $10,930,000 | +18.0% | 190,977 | 0.0% | 2.82% | +6.0% |
| Q2 2018 | $9,266,000 | -34.3% | 190,977 | -48.9% | 2.66% | +80.2% |
| Q1 2018 | $14,093,000 | -11.1% | 373,481 | 0.0% | 1.48% | +65.1% |
| Q4 2017 | $15,851,000 | +13.7% | 373,481 | 0.0% | 0.90% | +72.4% |
| Q3 2017 | $13,938,000 | -4.5% | 373,481 | -22.3% | 0.52% | +33.1% |
| Q2 2017 | $14,600,000 | +14.8% | 480,437 | 0.0% | 0.39% | -1.3% |
| Q1 2017 | $12,717,000 | -0.4% | 480,437 | -4.0% | 0.40% | +1.8% |
| Q4 2016 | $12,769,000 | -44.6% | 500,337 | -21.4% | 0.39% | -55.4% |
| Q3 2016 | $23,044,000 | -3.5% | 636,764 | -9.3% | 0.87% | -47.1% |
| Q2 2016 | $23,868,000 | +28.8% | 702,410 | 0.0% | 1.64% | +44.5% |
| Q1 2016 | $18,537,000 | -40.6% | 702,410 | +9.7% | 1.14% | -35.1% |
| Q4 2015 | $31,221,000 | +45.5% | 640,300 | -25.7% | 1.75% | +138.5% |
| Q3 2015 | $21,459,000 | -12.5% | 861,813 | +11.2% | 0.74% | +98.1% |
| Q2 2015 | $24,529,000 | -15.4% | 775,249 | +1.8% | 0.37% | -77.0% |
| Q1 2015 | $28,989,000 | -22.7% | 761,661 | -20.8% | 1.61% | -13.9% |
| Q4 2014 | $37,488,000 | +3.9% | 962,217 | -19.4% | 1.87% | +0.9% |
| Q3 2014 | $36,084,000 | -8.0% | 1,193,258 | +3.4% | 1.86% | -12.4% |
| Q2 2014 | $39,203,000 | +108.4% | 1,154,058 | +107.4% | 2.12% | +96.8% |
| Q1 2014 | $18,811,000 | -12.9% | 556,574 | 0.0% | 1.08% | -14.9% |
| Q4 2013 | $21,592,000 | – | 556,574 | – | 1.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |